tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KZIA Stock Latest News

Promising Clinical Developments and Financial Adjustments Drive Buy Rating for Kazia Therapeutics
RatingsPromising Clinical Developments and Financial Adjustments Drive Buy Rating for Kazia Therapeutics
9d ago
KZIA
Kazia Therapeutics target adjusted to $13 from $2 at H.C. Wainwright
PremiumThe Fly
Kazia Therapeutics target adjusted to $13 from $2 at H.C. Wainwright
9d ago
KZIA
Kazia Therapeutics Announces Promising Early Results in Breast Cancer Trial
PremiumCompany Announcements
Kazia Therapeutics Announces Promising Early Results in Breast Cancer Trial
9d ago
6K
KZIA
Kazia Therapeutics reports preliminary results from Phase 1b trial
PremiumThe Fly
Kazia Therapeutics reports preliminary results from Phase 1b trial
10d ago
KZIA
Kazia Therapeutics trading halted, volatility trading pause
PremiumThe Fly
Kazia Therapeutics trading halted, volatility trading pause
25d ago
KZIA
Kazia Therapeutics trading resumes
PremiumThe FlyKazia Therapeutics trading resumes
25d ago
KZIA
Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Data and Strategic Developments
Premium
Ratings
Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Data and Strategic Developments
1M ago
KZIA
Kazia Therapeutics Unveils Promising Preclinical Data for Paxalisib in Breast Cancer
Premium
Company Announcements
Kazia Therapeutics Unveils Promising Preclinical Data for Paxalisib in Breast Cancer
1M ago
6K
KZIA
Kazia Therapeutics trading resumes
PremiumThe Fly
Kazia Therapeutics trading resumes
1M ago
KZIA
Kazia Therapeutics trading halted, volatility trading pause
PremiumThe Fly
Kazia Therapeutics trading halted, volatility trading pause
1M ago
KZIA
Kazia Therapeutics announces publication of preclinical research on paxalisib
PremiumThe Fly
Kazia Therapeutics announces publication of preclinical research on paxalisib
1M ago
KZIA
Kazia Therapeutics Reports Half-Year Financials Amidst Ongoing Drug Development
PremiumCompany Announcements
Kazia Therapeutics Reports Half-Year Financials Amidst Ongoing Drug Development
1M ago
6K
KZIA
Kazia Therapeutics: Strategic Advancements and Market Opportunities Reinforce Buy Rating
PremiumRatingsKazia Therapeutics: Strategic Advancements and Market Opportunities Reinforce Buy Rating
1M ago
KZIA
Kazia Therapeutics Initiates Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Premium
Company Announcements
Kazia Therapeutics Initiates Phase 1b Trial of Paxalisib in Advanced Breast Cancer
1M ago
6K
KZIA
Kazia Therapeutics says first patient dosed in Phase 1b Trial of paxalisib
Premium
The Fly
Kazia Therapeutics says first patient dosed in Phase 1b Trial of paxalisib
1M ago
KZIA
Kazia Therapeutics Re-elects Director Robert Apple at AGM
PremiumCompany Announcements
Kazia Therapeutics Re-elects Director Robert Apple at AGM
2M ago
6K
KZIA
Kazia Therapeutics Advances Cancer Research Amid Nasdaq Compliance Challenge
PremiumCompany Announcements
Kazia Therapeutics Advances Cancer Research Amid Nasdaq Compliance Challenge
2M ago
6K
KZIA
Kazia Therapeutics trading halted, news pending
PremiumThe Fly
Kazia Therapeutics trading halted, news pending
3M ago
KZIA
Kazia Therapeutics Announces ADS Ratio Change to Maintain Nasdaq Compliance
PremiumCompany Announcements
Kazia Therapeutics Announces ADS Ratio Change to Maintain Nasdaq Compliance
3M ago
6K
KZIA
Kazia Therapeutics Sells Cantrixil IP Rights to Vivesto for $1 Million
PremiumCompany AnnouncementsKazia Therapeutics Sells Cantrixil IP Rights to Vivesto for $1 Million
4M ago
6K
KZIA
Kazia Therapeutics sells IP, trademarks rights to Cantrixil for $1M
Premium
The Fly
Kazia Therapeutics sells IP, trademarks rights to Cantrixil for $1M
4M ago
KZIA
Kazia Therapeutics Advances Cancer Drug Development with Strategic Moves and Promising Trial Results
Premium
Company Announcements
Kazia Therapeutics Advances Cancer Drug Development with Strategic Moves and Promising Trial Results
4M ago
6K
KZIA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >